The dawn of the liquid biopsy in the fight against cancer

ABSTRACT Cancer is a molecular disease associated with alterations in the genome, which, thanks to the highly improved sensitivity of mutation detection techniques, can be identified in cell-free DNA (cfDNA) circulating in blood, a method also called liquid biopsy. This is a non-invasive alternative...

Descripción completa

Detalles Bibliográficos
Autores principales: Domínguez Vigil, Irma Guadalupe, Moreno Martínez, Ana K., Wang, Julia Y., Roehrl, Michael H. A., Barrera Saldaña, Hugo Alberto
Formato: Artículo
Lenguaje:inglés
Publicado: 2017
Acceso en línea:http://eprints.uanl.mx/17421/1/280.pdf
Descripción
Sumario:ABSTRACT Cancer is a molecular disease associated with alterations in the genome, which, thanks to the highly improved sensitivity of mutation detection techniques, can be identified in cell-free DNA (cfDNA) circulating in blood, a method also called liquid biopsy. This is a non-invasive alternative to surgical biopsy and has the potential of revealing the molecular signature of tumors to aid in the individualization of treatments. In this review, we focus on cfDNA analysis, its advantages, and clinical applications employing genomic tools (NGS and dPCR) particularly in the field of oncology, and highlight its valuable contributions to early detection, prognosis, and prediction of treatment response.